Pentagon's testosterone policy questioned in Trump transgender ban case

A U.S. federal judge has scrutinized the Pentagon's policies regarding testosterone therapy, particularly the disparity in treatment for soldiers with low testosterone levels versus transgender service members.

Judge Ana Reyes in Washington questioned why the military offers hormone replacement therapy to personnel experiencing low testosterone while simultaneously restricting it for transgender men serving in the armed forces. This critical inquiry emerged during legal proceedings concerning the ban on transgender individuals in the military, a policy implemented by former President Donald Trump.

The judge's questioning highlights a potential inconsistency in the military's medical approach, prompting the Pentagon to clarify its rationale. The case seeks to address the fairness and legality of excluding transgender individuals from military service based on their need for hormone therapy.